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Abstract
Corticosteroid-binding globulin (CBG), a negative acute phase protein produced primarily in the liver, is responsible for the
transport of glucocorticoids (GCs). It also modulates the bioavailability of GCs, as only free or unbound steroids are
biologically active. Fluctuations in CBG levels therefore can directly affect GC bioavailability. This study investigates the
molecular mechanism whereby GCs inhibit the expression of CBG. GCs regulate gene expression via the glucocorticoid
receptor (GR), which either directly binds to DNA or acts indirectly via tethering to other DNA-bound transcription factors.
Although no GC-response elements (GRE) are present in the Cbg promoter, putative binding sites for C/EBPb, able to tether
to the GR, as well as HNF3a involved in GR signaling, are present. C/EBPb, but not HNF3a, was identified as an important
mediator of DEX-mediated inhibition of Cbg promoter activity by using specific deletion and mutant promoter reporter
constructs of Cbg. Furthermore, knockdown of C/EBPb protein expression reduced DEX-induced repression of CBG mRNA,
confirming C/EBPb’s involvement in GC-mediated CBG repression. Chromatin immunoprecipitation (ChIP) after DEX
treatment indicated increased co-recruitment of C/EBPb and GR to the Cbg promoter, while C/EBPb knockdown prevented
GR recruitment. Together, the results suggest that DEX repression of CBG involves tethering of the GR to C/EBPb.
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Introduction
Corticosteroid-binding globulin (CBG), also referred to as
transcortin or SerpinA6, is produced and secreted primarily by
hepatocytes in the liver and is considered a negative acute phase
protein (APP) [1,2]. It contains a single binding site for
glucocorticoids (GCs) and progesterone, both of which bind with
high affinity, with an estimated 80–90% of endogenous GCs
bound to CBG [3–6]. Although its main function is to transport
and modulate the bioavailability of these steroids, the role of CBG
is believed to extend to more than a carrier protein. It has been
proposed that CBG acts as a reservoir for GCs and directly
transports and releases these steroid hormones at target tissues
during inflammation [4,7–9].
According to the free hormone hypothesis, only the free fraction
of steroid hormone is biologically active and able to diffuse across
the plasma membrane of target tissues [10–12]. The ratio between
free and bound steroids depends on the number of binding sites
(concentration of plasma CBG) and the affinity (Kd) for the
binding sites. This implies that any changes in the levels of CBG
would modify the distribution of steroids to target tissues [4,13]
and indeed, free corticosterone levels in CBG (2/2) knockout
mice have been reported to be 10-times higher than in wild type
mice [8].
Several factors influence CBG production including a variety of
stressors and hormones [13–17]. GCs are the major hormone
secreted during stress and they mediate their biological effect
through binding to the glucocorticoid receptor (GR) whereby it is
able to modulate gene expression [18]. GCs also regulate the level
of their transport protein, CBG, in a negative feedback loop [4]. In
humans, plasma levels of CBG are suppressed during prolonged
exposure to GCs, whether endogenous, as in Cushing’s syndrome
[19], or exogenous, as during administration of synthetic GCs
[20]. A number of studies in rats also indicate that physiological
and physical stressors down-regulate CBG production [21,22].
Furthermore, the dramatic fall of CBG levels during stress, with
concomitant substantial (2 to 20-fold) increases in free GC levels,
merits its classification as a negative APP [1,2]. In humans, for
example, CBG levels are dramatically decreased during inflam-
mation and this drastic decrease in CBG levels has been associated
with impaired immune function [1,23,24].
Despite the fact that the human, mouse and rat CBG genes
(Cbg) have been cloned, no regulatory studies to identify possible
cis-acting sequence elements involved in GC-mediated regulation
of CBG have been done. [25–27]. However, DNase I foot-printing
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of the rat Cbg proximal promoter, has identified five protein-
binding sites (P1–P5) within 2236 bp from the transcription start
site in rat liver nuclear extract [25]. These five protein-binding
sites are also highly conserved in the human and mouse Cbg gene
Figure 1. Sequence alignment of the human, mouse, and rat Cbg proximal promoter sequences. The human Cbg promoter from2410 to
+29 bp (SERPINA6 ENSG00000170099), the mouse Cbg promoter from 2402 to +29 bp (Serpina6 ENSMUSG00000060807), and the rat Cbg promoter
from 2398 to +29 bp (Serpina6 ENSRNOG00000009438) relative to the transcription start site (+1) were aligned using Bioedit. Sequences were
obtained from Ensembl. The regions P1–P5, previously identified by DNase I foot printing within the rat Cbg promoter (25), are denoted as bold and
underlined letters with P1–P5 and resemble recognition sequences for HNF1, CP-2, DBP, HNF3a, and C/EBPb, respectively. Conserved residues,
relative to the rat Cbg promoter, are presented as shaded.
doi:10.1371/journal.pone.0110702.g001
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(Figure 1) [28]. They resemble recognition sequences for hepato-
cyte nuclear factor-1 beta (HNF1b; P1), CCAAT-binding protein-
2 (CP-2; P2), D-site-binding protein (DBP; P3), hepatocyte nuclear
factor-3 alpha (HNF3a; P4) and CAAT/enhancer binding protein
beta (C/EBPb or NF/IL6; P5), respectively (Figure 1) [25].
Electrophoretic mobility shift assays (EMSAs) have confirmed
that footprint one (P1) binds to HNF1b and footprint two (P2)
binds to CP2 [29].
Although the molecular mechanism by which GCs influence
CBG levels is unclear, the Cbg promoter has been shown to be
transcriptionally regulated via the GR [30–32]. However, while
the Cbg promoter is modulated by GCs [30,32,33], no glucocor-
ticoid response elements (GREs) seem to be present in the mouse,
rat or human CBG gene proximal promoters [25,28], suggesting
tethering of the GR to other transcription factors rather than
binding directly to DNA. Footprints P3–P5 in the Cbg promoter
resemble recognition sequences for DBP, HNF3a and C/EBPb or
NF-IL6 [25], and, although binding of these transcription factors
has not been confirmed, it is interesting to note that HNF3a and
C/EBPb have been reported to be important in GR-mediated
signaling [34,35]. Specifically, protein-protein interaction of the
GR with C/EBPb has been reported [35] and both C/EBPb and
HNF3a are considered pioneer transcription factors as they
increase chromatin accessibility at GC-responsive genes, thereby
facilitating GR interaction with GC-responsive promoters [36,37].
In this study, the molecular mechanism of action of GC-
mediated repression of CBG expression was investigated. Because
no consensus GR binding sites have been identified within the
CBG gene promoter, delineation of GR responsiveness within the
proximal rat CBG gene promoter was performed. This work
identified the region between 2295 and 2145bp 59 of the
transcription start, which contains putative binding sites for C/
EBPb, HNF3a and DBP, as being important for GC responsive-
ness. Mutation of these transcription factor-binding sites narrowed
down the site for GC responsiveness to the C/EBPb binding site.
Knockdown of C/EBPb with siRNA corroborated the require-
ment of C/EBPb for GC-induced repression of CBG, while ChIP
and re-ChIP experiments confirmed that both GR and C/EBPb
bind concomitantly to the Cbg promoter and that GR-binding is
attenuated when C/EBPb is ablated. This study is the first to
report on the molecular mechanism of how GCs regulate the
expression of their carrier protein, CBG.
Materials and Methods
Test compounds and tissue culture
Dexamethasone (DEX) and mifepristone (RU486) were ob-
tained from Sigma-Aldrich. Steroids were dissolved and diluted in
ethanol. Concentration of ethanol (vehicle) added to cells was
0.1%. Dulbecco’s modified eagle medium (DMEM) and penicillin-
streptomycin (Penstrep) solution were purchased from Gibco and
fetal bovine serum (FBS) from Sterilab or Adcock Ingram. L-
glutamine was purchased from Sigma-Aldrich. The mouse
hepatoma (BWTG3, a kind gift from Guy Haegeman, University
of Gent, Belgium [32]), human hepatoma (HepG2, obtained from
the Medical research council, Tygerberg, South Africa who
obtained it from ATCC - product number HB-8065D) and
monkey kidney (COS-7, received from Guy Haegeman, Univer-
sity of Gent, Belgium who obtained it from ATCC - product
number CRL-1651) cell-lines were grown in Falcon T150 or T75
flasks at 37uC in a 5% CO2 atmosphere, in DMEM supplemented
with 10% FBS, Penstrep (40 U/ml) and L-glutamine (30 g/l).
Plasmids
The rat GRa (pSVGR1) expression vector, which was kindly
provided by S. Okret (Dept. of Medical Nutrition, Karolinska
Institute, Sweden), was constructed as described in Miesfeld et al.,
1986 (UCSF) and contains the SV40 enhancer/early promoter
region, the coding region of the rat GRa cDNA and the SV40
polyA region [38]. Various rat Cbg-luciferase reporter plasmids
were constructed by G.L. Hammond (London regional Cancer
Centre, London, Canada) of which the rat Cbg-295Luc construct
contains the five protein-binding sites, identified by DNase I foot
printing [25]. The b-gal reporter plasmid (pPGKbGopbA),
constitutively expressing a neomycin-resistant/b-galactosidase
fusion protein under the control of the pPGK promoter from
the mouse housekeeping enzyme, 3-phosphoglycerate kinase, was
a gift from Dr P. Soriano (Fred Hutchinson Cancer Research
Centre, Seattle, WA). Weihua Xiao (NCI-Frederick Cancer
Research and Development center, Frederick, USA) kindly
provided the CAAT/enhancer binding protein (C/EBPb) expres-
sion construct.
Ethics Statement
The Animal Research Ethics committee of Subcommittee B at
Stellenbosch University ethically approved rat studies prior to
initiation of experimental procedures (reference CS29/022000).
All efforts were made to minimize suffering.
Rat studies
Forty adult male Wistar rats were divided into four groups of
ten rats each. Group 1 (Control) acted as the control sedentary
group and underwent no intervention treatment. Group 2 (Run)
was housed in rat wheels designed for this purpose and allowed to
run at will and subjected to voluntary exercise stress only. Group 3
(Swim) was subjected to an involuntary swimming exercise of one
hour per day for the duration of the experiment (10 days). Group 4
Figure 2. Regulation of rat CBG mRNA levels by physiological
stressors. Adult male Wistar rats were subjected to voluntary running
(Run), involuntary swimming (Swim) or restraint (Restraint) treatment
for ten days (see Experimental Procedures). Rats were sacrificed and
livers removed for RNA isolation, which was analyzed by Northern
blotting. (A) Representative Northern blot of CBG and b-actin mRNA
levels. (B) Quantification of CBG mRNA expression levels normalized to
liver b-actin mRNA levels. Statistical analysis was done relative to the
corresponding control rats, using one-way ANOVA followed by
Dunnett’s multiple comparison’s post-test (***: p,0.001; ****:p,
0.0001).
doi:10.1371/journal.pone.0110702.g002
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(Restraint) was subjected to restraint for one hour per day in small
Perspex cages (8611617 cm) for the 10 days of the experiment.
Rats were fed rat chow and water ad libitum, and were housed in
groups of three or four in standard rat cages, except for the RUN
group, which was housed individually in specially designed rat
wheels. The rats were subjected to a 12 hr light-dark cycle and
weighed daily. Since rats are nocturnal animals, all interventions
were carried out in the late afternoon. All rats were sacrificed by
decapitation on day 11 of the protocol at noon, to counter diurnal
changes in endocrine measures. The livers were removed and total
ribonucleic acid (RNA) was immediately extracted according to
the trizol method as described by the manufacturer (Sigma). After
extraction, the final RNA pellet was dissolved in 50 ml formazol
(Molecular research center, Inc) and kept at –80uC until used. The
RNA concentration was determined by reading the absorbance at
260 nm. CBG mRNA expression was quantified using Northern
blotting as described below.
CBG mRNA and protein expression determination
For quantification of CBG mRNA expression in rat livers,
Northern blotting was done. Total RNA (20 mg) was loaded and
run on a 1% formaldehyde-agarose gel and transferred to a nylon
membrane (Hybond-N+, Amersham). To check RNA preparation
integrity, EtBr staining was used to demonstrate the presence of
intact 18S and 28S ribosomal bands. RNA was fixed on the
membrane by using a UV crosslinking for 12 s. The membrane
was prehybridized in a hybridization oven at 50uC for 1 hr with
prewarmed Dig easy Hyb solution (Roche). Plasmids carrying
human Cbg complementary DNAs (cDNA kindly provided by
G.L. Hammond) were amplified in a DH5a-competent Esche-
richia coli strain and digested with EcoRI. Cbg inserts were
isolated by agarose gel electrophoresis. The expected Cbg cDNA
of 1.2 kb was obtained. Hybridization was performed overnight at
50uC with [32P]-Cbg cDNA probes labeled with [a-32P] deoxy-
cytidine triphosphate using the random priming technique
(Amersham megaprime labeling kit). Membranes were washed
twice for 5 min in 2xSSC, 0.1% SDS at room temperature,
followed by two washings for 15 min in 0.1xSSC, 0.1% SDS at
Figure 3. DEX treatment down-regulates CBG mRNA and protein levels in hepatoma cell lines. The effect of DEX on CBG mRNA and
protein levels was investigated in a human hepatoma cell line, HepG2 (A&B) and in a mouse hepatoma cell line, BWTG3 (C&D). Both cell lines (HepG2
& BWTG3) were incubated with vehicle control (0.1% EtOH) or 1 nM DEX for 8 hrs to determine CBG mRNA (A&C) and protein expression (B&D). Total
RNA was isolated and reversed transcribed to cDNA. Real-time quantitative PCR (qPCR) was performed to determine the mRNA expression levels of
CBG and internal standards (18S for HepG2 and GAPDH for BWTG3 cells). CBG protein expression was analyzed by means of Western blotting. GAPDH
protein expression was used as loading control. Statistical analysis was done relative to the corresponding vehicle control (0.1% EtOH), using students
unpaired t-test (*: p,0.05; **: p,0.01; ***:p,0.001).
doi:10.1371/journal.pone.0110702.g003
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50uC. Membranes were wrapped in cling wrap and underwent
autoradiography for between 24- and 48 hrs at –70uC. Autora-
diograms were scanned using the densitometry program UN-
SCAN-IT. Membranes were stripped using a hot 0.5% SDS
solution and reprobed with [32P]b–actin cDNA (provided by H.
Okayama).
For CBG mRNA analysis in both BWTG3 and HepG2 cells,
cells were plated at a density of 16105 cells/well in a 12-well plate,
treated with vehicle control (01% EtOH) or 1 nM DEX for 8 hrs,
after which total RNA was isolated using TRI Reagent (Sigma-
Aldrich) as per the manufacture’s protocol. The integrity of the
28S and 18S ribosomal bands was confirmed on denaturing
formaldehyde agarose gels.
Total RNA (1 mg) was reverse transcribed using the ImProm-II
Reverse Transcription System cDNA synthesis kit (Promega).
Subsequently, semi-quantitative real time PCR was performed
using the Kapa SYBR green (Kapa) and the Corbett real-time
PCR machine or StepOne Plus PCR instrument (Applied
Biosystems). Human CBG gene expression was measured using
the following primer pair: hCBG (FWD) 59–GAACTACGTGGG-
CAATGGGA-39 and hCBG (REV) 59-CCTGCGGAC-
CACCTGTTAAT-39. Mouse CBG gene expression was mea-
sured using the following primer set: mCbg (FWD) 59-AGG
CTGTCACTGATGAGGAT-39and mCbg (REV) 59-CTGAAC-
TATCCAGGTCTGAG-39. Expression of 18S was used as
internal control in HepG2 cells and measured with the following
primer pair: h18S (FWD) 59-GAGAAACGGCTACCACATC-
CAAG 239 and h18S (REV) 59- CCTCCAATG-
GATCCTCGTTA 239. GAPDH served as an internal control
in BWTG3 cells and expression was measured using the following
primer set (FWD) 59- GTCCATGCCATCACTGCCA-39,
GAPDH (REV) 59 GGCATCGAAGGTGGAAGAG-39. Melting
curve analysis was performed to confirm amplification of a single
product in each sample. Relative transcript levels were calculated
using the method described by Pfaffl et al., 2001 [39], and were
normalized to the relative 18S (HepG2 cells) or GAPDH (BWTG3
cells) transcript levels.
For the determination of CBG protein expression, cell lysates
were subjected to Western blot analysis using either a mouse CBG-
specific antibody (SerpinA6 (T-15) sc-79063 from Santa Cruz
Biotechnology) or the mouse or human CBG-specific antibody
(ab107368 from Abcam).
Rat Cbg promoter reporter studies
For transient transfections 56104 BWTG3 cells/well were
plated in DMEM supplemented with culture medium in 24-well
tissue culture plates. Cells were transfected 24 hrs later using
Fugene6 transfection reagent (3 ml/well) as described by the
Figure 4. DEX-mediated repression of the rat Cbg295Luc
promoter reporter construct is dependent on GR. (A) DEX
represses the rat Cbg295Luc promoter reporter construct in a dose
dependent manner in BWTG3 cells. The cells were transiently
transfected with rat Cbg295Luc and with a b-galactosidase expression
plasmid (pPGKbGopbA) to monitor for transfection efficiency. Twenty-
four hrs after transfection, cells were treated with increasing
concentrations of DEX and incubated for 24 hrs. Luciferase values were
normalized for b–galactosidase activity and plotted as a percentage of
the average control. EC50 values were determined by fitting a dose
response curve. (B) Effect of co-transfected GR expression vector on
transrepression of the rat Cbg295Luc promoter reporter construct by
DEX was investigated in BWTG3 cells. The cells were transiently
transfected with rat Cbg295Luc, with or without the rat GRa expression
vector, pSVGR1. In addition, a b-galactosidase expression plasmid
(pPGKbGopbA) was co-transfected to monitor for transfection efficien-
cy. Twenty-four hrs after transfection, cells were treated with 1 mM DEX
or vehicle control (0.1% EtOH) and incubated for 24 hrs. Luciferase
values were normalized to b–galactosidase and values plotted as a
percentage of the average vehicle control. Statistical analysis was done
to (i) compare values in presence of DEX relative to the corresponding
control using one-way ANOVA followed by Dunnett’s multiple
comparison’s posttest (***: p,0.001) and to (ii) compare values without
GR (–rGRa) to values with co-transfected GR (+rGRa) using two-way
ANOVA followed by Bonferonni’s multiple comparison’s posttest (##:
p,0.01). (B) Effect of the glucocorticoid antagonist, RU486, on
transrepression was determined by transiently transfecting BWTG3
cells with the rat Cbg295Luc promoter reporter. Twenty-four hrs after
transfection cells were treated with 1 mM DEX and/or 20 mM RU486, as
indicated. Luciferase values were normalized to b–galactosidase and
values are plotted as a percentage of the average vehicle control.
Statistical analysis was done to (i) compare values in presence of test
compounds relative to vehicle control (0.1% EtOH) (***: p,0.001) and
to (ii) compare values of each compound tested relative to the
combined treatment of DEX and RU486 (DEX+RU486) (###: p,0.001),
using one-way ANOVA followed by Bonferonni’s multiple comparison’s
posttest comparing all columns.
doi:10.1371/journal.pone.0110702.g004
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manufacturer (Roche). All promoter reporter constructs
(rCbg295Luc, rCbg145Luc or rCbg1200Luc) were transfected
using 360 ng of Luc reporter plasmid with or without 200 ng of rat
(pSVGR1), as indicated in the figure legends. In addition, 40 ng of
b–galactosidase reporter plasmid (pPGKbGopbA) was included in
most samples as internal standard for transfection efficiency. If b–
galactosidase was not used for normalization of luciferase values,
these were normalized to total protein [40]. Cells were treated for
24 hrs with different concentrations of DEX and/or 20 mM
RU486, as indicated in figure legends, 24 hrs after transfection,
after which cells were washed with pre-warmed PBS and lysed
with 100 ml lysis buffer (PE Biosystems). Harvested cells were
frozen at –20uC overnight. Luciferase and b-galactosidase
activities were determined using the luciferase assay kit (Promega)
and the Galacto-star assay kit (PE Biosystems) according to the
instructions of the manufacturers. Light emission was measured in
a luminoskan plate reader (Labsystems) and luciferase values were
normalized for b–galactosidase activity and plotted as a percent-
age of the average control. EC50 values were determined by fitting
a dose response curve.
Site-directed mutagenesis
By means of site-directed mutagenesis (Stratagene Quick
Mutagenesis kit), specific point mutations were introduced at the
regulatory sites for C/EBPb (P5), HNF3a (P4), and DBP (P3) of
the rat Cbg295Luc promoter, by using the following primer sets:
P3MUT1 59 GTTAATTTCTAGAATTGCATGTTTACC
39(new XbaI), P3MUT2 59 GTTAATTTGCAGAATTC-
CATGTTTACC 39 (new EcoRI), P3MUT3 59 GTTAATTTG-
CAGGATCCCATGTTTACC 39 (new BamHI), P4MUT1 59
CAGCCACACTTAGATCTTAAAAATAAAACTAGGG
39(new BglII), P4MUT2 59 CAGCCACACTTCTAGAT-
TAAAAATAAAACTAGGG 39(new XbaI), P5MUT1 59 CCA-
CAAATACCATGGCAACTCCAGC 39 (new NcoI), P5MUT2
59 CAAATACTGACGCGGATCCAGCCACAC 39 (new
BamHI/Gsu I deleted).
Mutations were designed to create or remove restriction sites
and corresponding mutated plasmid clones were sequence-
verified. Since the sequence verification failed for the P4MUT1
mutation, this mutant was not further evaluated in transfection
studies. All other sequence approved mutated plasmid clones were
used in transfection studies.
The rat Cbg295Luc promoter reporter constructs (360 ng
plamid DNA) with various mutations at the regulatory sites for
C/EBPb (P5), HNF3a (P4), and DBP (P3) were subsequently
transiently transfected into COS-7 cells, which were plated as
described for BWTG3 cells in 24-well culture plates. The
transiently transfected cells were treated with 10 mM DEX or
vehicle control (0.1% EtOH) for 24 hrs. Luciferase activity was
compared relative to the corresponding control and normalized to
protein levels.
Chromatin immunoprecipitation assay
Twenty-four hrs after seeding, the culture medium of BWTG3
cells was replaced with DMEM, supplemented with 10% charcoal-
stripped fetal bovine serum (FBS), penicillin-streptomycin (40 U/
ml) and L-glutamine (30 g/l), and incubated for 24 hrs. The
following day cells were either treated with 10 mMDEX or vehicle
alone for 2 hrs and were then cross-linked with formaldehyde at a
final concentration of 1% for 10 min at 37uC. The cross-linking
reaction was stopped by the addition of glycine to a final
concentration of 0.125 M for 5 min at room temperature while
shaking. Cells were washed with ice-cold PBS, harvested,
resuspended in 500 ml nuclear lysis buffer (1% (w/v) SDS,
50 mM Tris-HCL, pH 8.0, 10 mM EDTA plus 1 tablet 1 x
Complete Mini Protease Inhibitor Cocktail per 10 ml) and
sonicated at 75% Power, for 25 cycles at 20 sec per cycle, with
20 sec intervals between pulses, using the Misonix Ultrasonic
Liquid Processor. The average chromatin size after sonication was
about 150–500 bp. Sonicated chromatin was then centrifuged for
10 min at 15 000 g at 4uC and chromatin-containing supernatant
was transferred to a clean micro centrifuge tube. After quantifi-
cation by spectrophotometry, 100 mg sonicated chromatin was
diluted with IP dilution buffer (0.01% (w/v) SDS, 20 mM Tris-
HCL, pH 8.0, 1.1% (v/v) Triton X-100, 167 mM NaCl, 1.2 mM
EDTA plus 1 x Complete Mini Protease Inhibitor Cocktail at 1
tablet per 10 ml), followed by pre-clearing for 1 hr with 20 ml
50:50 (v/v) pre-blocked Protein A/G PLUS beads (sc-2003, Santa
Cruz Biotechnology, USA) on a rotating wheel at 4uC. Pre-cleared
chromatin was incubated with 2 mg primary antibody (anti-GR
(GR-H300 sc-8992), anti-C/EBPb (C/EBb-C19 sc-150), or anti-
IgG antibody (sc-2027), all from Santa Cruz Biotechnology)
overnight at 4uC on a rotating wheel. The following day, the
mixture was incubated with 40 ml 50:50 (v/v) pre-blocked Protein
Figure 5. Delineation of DEX-mediated repression of the rat Cbg promoter. The rat Cbg1200Luc, rat Cbg295Luc and rat Cbgl45Luc promoter
reporter constructs were transiently transfected into BWTG3 cells. A b-galactosidase expression plasmid (pPGKbGopbA) was co-transfected to
monitor for transfection efficiency. Twenty-four hrs after transfection, cells were treated with 10 mM DEX or vehicle control (0.1% EtOH) and
incubated for 24 hrs. Luciferase activity was determined and normalized to b–galactosidase activity. Results are plotted as a percentage of the
average vehicle control (0.1% EtOH), which was set as 100%. Statistical analysis was done to compare treatments in the presence of DEX relative to
vehicle control (0.1% EtOH), using one-way ANOVA followed by Dunnett’s multiple comparison’s posttest (**: p,0.01).
doi:10.1371/journal.pone.0110702.g005
Down-Regulation of CBG by Glucocorticoids Involves C/EBPb
PLOS ONE | www.plosone.org 6 October 2014 | Volume 9 | Issue 10 | e110702
A/G PLUS beads on a rotating wheel for 6 hrs at 4uC. The
samples were then centrifuged at 5000 g for 1 min at 4uC and the
pellet was washed three times with 1 ml wash buffers with
increasing salt concentration (150 mM –500 mM NaCl) and
followed by three washes with 1 ml TE buffer. After washing, the
pellet was resuspended in 300 ml elution buffer (1% (w/v) SDS and
Figure 6. DEX responsiveness is abolished when the C/EBPb site is mutated. The rat Cbg295Luc promoter reporter construct with various
mutations at regulatory sites C/EBPb (P5), HNF3 (P4), and DBP (P3) were transiently transfected into COS-7 cells. Transfected cells were treated with
10 mM DEX or vehicle control (0.1% EtOH) for 24 hrs. Luciferase activity was measured and normalized to protein concentrations. Results were
compared relative to the corresponding vehicle control (0.1% EtOH). For statistical analysis two-way ANOVA was done with Bonferroni’s multiple
comparison as post-test to compare DEX-induced treatments with each corresponding control (0.1% EtOH) (*: p,0.05; **: p,0.01; ***: p,0.001).
doi:10.1371/journal.pone.0110702.g006
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100 mM NaHCO3). Cross-linking was reversed by the addition of
NaCl at a final concentration of 300 nM, followed by incubation
overnight at 65uC. Thereafter a further incubation at 45uC for
1 hr in the presence of 15 nM EDTA, 125 nM Tris-HCL and
60 ng/ml proteinase K (Roche Applied Science) was performed.
Chromatin DNA was purified using NucleoSpin Extract II nucleic
acid purification kit (Macherey-Nagel). Purified chromatin DNA
was amplified by semi-quantitative real-time PCR using primers,
spanning (1) the regions P5 to P1 FWD:59-
CCCTGCCAGGTGGCACAGG-39; REV:59-GGAGAGGGG-
CAGTGGCCTTC-39 of the mCbg promoter and (2) a non-
specific region within the mCbg promoter (position 2141/235),
FWD:59- AGGGGGTGGGGACCACCAAA-39; REV:59-
AAGGCTTCGGGGAGACTCCTACTA-39. ChIP results were
normalised as described by Aparicio and co-workers [41]. Briefly,
Ct values for amplification of purified IP chromatin DNA from the
regions of interest were normalized to Ct values from a control
non-specific region within the mCbg promoter, as well as
normalized input. DEX treatment did not affect recruitment of
transcription factors to the non-specific region (data not shown).
In re-ChIP experiments, chromatin-antibody complexes were
first eluted in 100 ml elution buffer containing 10 mM dithiothre-
itol and 1% SDS at 37uC for 30 min whilst shaking. The eluted
samples were diluted 20 times with IP dilution buffer and
subjected again to the ChIP procedure with an antibody specific
for C/EBPb (C-19 sc-150 Santa Cruz Biotechnology). The first
immunoprecipitation with an anti-GR antibody served as internal
control. Ct values from re-ChIP results were normalized to Ct
values from IgG vehicle control, which was set as 1.
Small interference RNA (siRNA) transfections
BWTG3 cells plated at a density of 16 105 cells/well in a 12-
well culture plate were transfected with 10 nM validated C/EBPb
siRNA, which consist of four different validated siRNA oligo’s
(Qiagen Flexitube GeneSolution cat# GS12608) directed against
the mouse C/EBPb, or validated non-silencing scrambled
sequence control (NSC) siRNA (cat#1027310) (Qiagen), using
HiPerfect transfection reagent (Qiagen) as per the manufacturer’s
instructions. Briefly, C/EBPb or NSC siRNA was diluted in pre-
warmed Optimem medium (Invitrogen Gibco-BRL Life Technol-
ogies) to which 4.5 ml transfection reagent was added. Cells were
incubated for 24 hrs before being treated with 1 nM DEX for
8 hrs or vehicle control in unsupplemented medium, after which
RNA was harvested and CBG gene expression analyzed by semi-
quantitative real time PCR. In addition, lysates were prepared for
Western blot analysis using a CBG-specific antibody (ab107368)
from Abcam.
For ChIP, where C/EBPb protein expression was silenced,
BWTG3 cells were plated in 10-cm tissue culture dishes at a
density of 16107 cells per dish. Twenty-four hours after seeding,
cells were transfected as described above only with amounts
adjusted for the larger seeding vessel. Briefly, 150 nM validated
C/EBPb siRNA directed against the mouse C/EBPb, or validated
NSC siRNA were incubated together with pre-warmed Optimem
medium and 67.5 ml HiPerfect transfection reagent as per the
manufacturer’s instructions whereafter it was added to the cells.
Twenty-four hours after siRNA transfection the ChIP protocol
was followed as described earlier. Briefly, Ct values for amplifi-
cation of purified IP chromatin DNA from the regions of interest
were normalized to Ct values from a control non-specific region
within the mCbg promoter, normalized input, and NSC vehicle
control, which was set as 1. Protein knockdown for all experiments
was verified by Western blot analysis.
Data and statistical analysis
Data is expressed as the mean 6 SEM for triplicate values of
each experiment and analyzed by ANOVA followed by the
Dunnett’s, or Bonferroni’s multiple comparison’s posttest (p,
0.001***; p,0.01**; p,0.05*; p.0.5 not significant) or, when
comparing two groups, only one-tailed paired t-test was used.
Each experiment was repeated at least twice. Graph Pad PrismH
was used for graphical representation and statistical analysis.
Figure 7. The GR is recruited to the mouse Cbg promoter in response to DEX. BWTG3 cells were treated with 10 mM DEX for 2 hrs
followed by ChIP assay, as described in the Material and Methods. Occupancy of GR protein on the endogenous mouse Cbg promoter was
detected using primers encompassing the regions defined as P5 to P1 (A). In addition, C/EBPb recruitment onto the mCbg promoter encompassing
regions P5 to P1 was determined (B). Co-immunoprecipitated DNA fragments and input DNA were analyzed by qPCR and results shown are
normalized to a non-specific region of the mCbg promoter, input and the vehicle control (0.1% EtOH) of a non-specific region, which was set as 1.
Statistical analysis was done to compare recruitment of the GR in response to DEX relative to vehicle control (0.1% EtOH), using student’s paired t-test
(*: p,0.05; ***:p,0.001).
doi:10.1371/journal.pone.0110702.g007
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Figure 8. Decrease of C/EBPb protein expression attenuates DEX-induced repression of CBG mRNA and protein levels and reduces
GR recruitment to the mouse Cbg promoter. To determine CBG mRNA and protein expression in response to decreased C/EBPb protein
expression, BWTG3 cells were transfected with non-specific siRNA (NSC) or with siRNA specific for the mouse C/EBPb. As a control for C/EBPb
knockdown, total protein from untransfected (UT) BWTG3 cells, as well as from BWTG3 cells transfected with NSC or C/EBPb siRNA, was harvested to
perform Western blotting. A representative blot of two independent experiments is shown (A). Cells were treated with 1 nM DEX or vehicle control
(0.1% EtOH) for 8 hrs, 24 hrs after transfection. (B) Relative CBG mRNA expression levels were measured by qPCR and normalized to relative GAPDH.
Relative fold-expression of CBG mRNA levels were normalized to respective vehicle control (0.1% EtOH) which was set as 1. (C) CBG protein
expression levels were analyzed by means of Western blotting, quantified and normalized to relative GAPDH expression. Relative CBG protein
expression were normalized to the respective vehicle control (0.1% EtOH), which was set as 1. (D) A representative Western blot of CBG protein
expression is shown. For (B&C) statistical analysis was done to compare CBG mRNA and protein expression in response to decreased C/EBPb protein
expression using two-way ANOVA with Bonferroni’ multiple comparison as post-test (*: p,0.05; **:p,0.01; ***:p,0.001). (E) To examine the effect of
decreased C/EBPb protein expression on GR recruitment to the mouse Cbg promoter, BWTG3 cells were transfected with siRNA as described above.
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Results
Regulation of CBG mRNA by physical and psychological
stressors in rats
Numerous reports have indicated that CBG expression is
influenced by both physical and psychological stressors [21,42].
With this in mind, adult male Wistar rats were subjected to a mild
psychological stressor, namely, restraint, and two physical stressors
of diverse intensity, namely, voluntary running (mild stressor) or
involuntary swimming (severe stressor). Intermittent stress expo-
sure continued for ten days after which rats were sacrificed and
livers removed for RNA isolation (Figure 2). Of all the stressful
events, restraint affected CBG mRNA expression most signifi-
cantly (p,0.0001) with a 55% reduction, followed by involuntary
swimming (p,0.001) with a 27% reduction. In contrast, voluntary
running had little effect on CBG mRNA expression. These
findings are in agreement with the literature which has reported a
decrease in CBG expression due to stress [4,20,21,42].
Regulation of CBG mRNA and protein levels by DEX in
hepatic cell lines
During stress endogenous GCs are released, which are believed
to be the mediators responsible for the in vivo decrease in CBG
expression [30]. In addition, the potent GC, DEX, has been
shown to decrease CBG mRNA in mice [30]. Thus, to establish
whether the effect observed by us, and others, in vivo regarding
CBG expression is also seen in vitro, human and mouse hepatoma
cell lines, HepG2 and BWTG3, respectively, were treated with
DEX. Both CBG mRNA and protein levels were evaluated
(Figure 3). The results show that DEX at 1 nM significantly (p,
0.05) decreased CBG mRNA and protein expression in both cell
lines tested. As fold decrease in CBG expression was similar for
both mRNA and protein, this may suggest that regulation occurs
primarily at the transcriptional level. Our results in HepG2 cells
are in contrast to a previous study showing no effect of 1 mMDEX
at mRNA and on protein levels [43].
The GR is involved in DEX-mediated repression of CBG
expression
Once it was established that endogenous CBG expression is
repressed by the synthetic glucocorticoid, DEX, we next tested
whether the rCbg295Luc promoter reporter construct would
behave similarly. BWTG3 cells were transiently transfected with
the rCbg295Luc promoter reporter construct in the presence of
increasing DEX concentrations (Figure 4A). The dose-response
curve indicates that DEX represses the rCbg295Luc promoter
reporter construct with an EC50 value of 3.6 nM. Although
repression at 1 nM is thus less than seen for the endogenous rCbg
gene (Figure 3C) at around 1 mM DEX, maximal repression is
observed.’’
Having established that DEX can repress the rCbg295Luc
promoter reporter construct in a dose-dependent manner, we next
tested whether this transrepression potential is dependent on the
glucocorticoid receptor (GR) as glucocorticoids act via this ligand-
activated steroid receptor [18]. BWTG3 cells were transiently
transfected with the rCbg295Luc promoter reporter construct in
the presence or absence of the transfected rGRa expression vector
(Figure 4B). Co-transfection with rGRa in BWTG3 cells signifi-
cantly (p,0.01) increased DEX-induced (1 mM) repression of
rCbg promoter activity (Figure 4B). GR dependence of DEX-
mediated inhibition of rCbg promoter activity was further
confirmed as co-treatment with the GR antagonist, RU486,
significantly (p,0.001) abolished DEX-mediated repression of
rCbg promoter activity (Figure 4C). These two results strongly
suggest that DEX-induced repression of rCbg promoter activity
acts through the GR and is in agreement with results obtained by
Cole and co-workers [30].
Delineation of DEX responsiveness within the rCbg
proximal promoter reporter construct
Although we and others have shown involvement of the GR in
DEX-induced repression of CBG, no consensus binding element(s)
for the GR could be detected in the rCbg promoter by
transcription factor motif analysis. Thus, next, we wanted to
determine which region of the proximal Cbg promoter plays a role
in GR-mediated modulation of CBG expression. BWTG3 cells
were therefore transiently transfected with the full length rCbg
proximal promoter reporter construct (rat Cbg1200Luc), as well as
with the truncated rCbg promoter reporter constructs (rat
Cbg295Luc and rat Cbg145Luc) (Figure 5). The rat Cbg295Luc
promoter reporter construct contains the five protein-binding sites
(P1–P5), identified by DNase I foot printing, which resemble
recognition sequences for hepatocyte nuclear factor-1 (HNF1b),
CCAAT-binding protein-2 (CP-2), D-site binding protein (DBP),
hepatocyte nuclear factor-3 (HNF3a) and CAAT/enhancer-
binding protein (C/EBPb), whereas the rat Cbg145Luc promoter
reporter construct contains only HNF1b and CP-2 [25].
The glucocorticoid, DEX, at 1 mM, significantly transrepressed
(p,0.01) the transiently transfected rat Cbg1200Luc and rat
Cbg295Luc promoter reporter constructs, as was observed with
the endogenous gene (Figure 3). In contrast, DEX had no effect on
the rat Cbg145Luc promoter reporter activity, which contained
only the HNF1b and CP-2 binding sites, suggesting that these two
sites are not important for GC-mediated repression of Cbg
promoter activity (Figure 5).
Twenty-four hrs after transfection, cells were treated with 10 mM DEX or vehicle control (0.1% EtOH) for 2 hrs followed by ChIP assay, as described in
the Material and Methods. Occupancy of GR protein on the endogenous mouse Cbg promoter was detected using primers encompassing the regions
defined as P5 to P1. Co-immunoprecipitated DNA fragments and input DNA were analyzed by qPCR and results shown are normalized to a non-
specific region within the mCbg promoter as well as input and expressed relative to NSC vehicle control (0.1% EtOH), which was set as 1. Statistical
analysis was done to compare recruitment of the GR relative to NSC vehicle control (0.1% EtOH), using one-way ANOVA followed by Dunnett’s
multiple comparison’s posttest (*: p,0.05). (F) Co-recruitment of the C/EBPb and GR to the mouse Cbg promoter in response to DEX. BWTG3 cells
were treated with 10 mM DEX for 2 hrs followed by re-ChIP assay, where cross-linked cell lysates were subjected to immunoprecipitation, first with an
anti-GR-specific antibody (data not shown) and then with a control IgG or an anti-C/EBPb-specific antibody (IP2). The occupancy of GR and C/EBPb
protein at the Cbg promoter, encompassing regions P5 to P1 were detected using primers designed against the indicated region. Co-
immunoprecipitated DNA fragments and input DNA were analyzed by qPCR. Results shown were normalized to IgG for second IP as well as input and
expressed relative to IgG vehicle control for the second IP (0.1% EtOH), which was set as 1. Statistical analysis was done to compare DEX-induced
protein recruitment to the Cbg promoter relative to IgG vehicle control (0.1% EtOH), using one-way ANOVA with Dunnett’s multiple comparison as
post-test (*: p,0.05).
doi:10.1371/journal.pone.0110702.g008
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GC responsiveness is abolished, when the C/EBPb site in
the rCbg proximal promoter reporter construct is
mutated
Following the delineation study of the Cbg promoter (Figure 5),
which identified the region containing the binding elements for C/
EBPb (P5), HNF3a (P4), and DBP (P3) as being important for
DEX-mediated repression of CBG, site-directed mutagenesis of
the above mentioned regulatory binding elements was performed.
DEX (10 mM) was still able to significantly down-regulate Cbg
promoter activity, when HNF3a (P4) and DBP (P3) sites were
mutated (Figure 6). In contrast, mutations of the C/EBPb-binding
site resulted in a loss of DEX-induced repression (Figure 6),
suggesting that the C/EBPb cis-regulatory site is important for
DEX-mediated regulation of CBG.
The GR is recruited to the C/EBPb cis-regulatory site in
the Cbg gene promoter
Having shown that the GR is required for DEX-mediated
inhibition of CBG (Figure 4) and that mutating the C/EBPb
regulatory site influences this repression (Figure 6), we next
wanted to investigate whether the GR occupies the endogenous
mCbg promoter by means of a ChIP assay.
In response to DEX treatment, significant enrichment of GR
occurred at the endogenous mCbg promoter (P5 to P1) relative to
a control non-specific region within the mCbg promoter
(Figure 7A). This area of the mCbg promoter contains the C/
EBPb-binding element (P5). Furthermore, significant DEX-
induced C/EBPb recruitment to the Cbg promoter was also
observed (Figure 7B) substantiating for the first time that C/EBPb
does indeed bind to the Cbg proximal promoter. These results,
taken together with the loss of DEX-induced repression of the Cbg
promoter when the C/EBPb cis-regulatory element was mutated
(Figure 6), suggests that the GR is binding to the C/EBPb-binding
element (P5).
C/EBPb knockdown attenuates DEX-mediated CBG
mRNA and protein repression and GR recruitment to the
Cbg promoter
Due to recruitment of the GR to the Cbg promoter in the
absence of any known GR-binding element, we postulated that
GR-mediated repression of CBG expression is via interaction with
C/EBPb through a tethering mechanism. This argument is
strengthened by the observations identifying the C/EBPb-binding
element as important for DEX responsiveness (Figure 6). Knock-
down studies of C/EBPb protein were thus performed to confirm
the involvement of C/EBPb in DEX-induced repression of CBG
(Figure 8). A decrease in C/EBPb protein expression was achieved
using a mixture of four validated siRNA oligo’s specific for the
mouse C/EBPb (Figure 8A).
The non-specific scrambled siRNA oligo’s (NSC) had no effect
on C/EBPb expression (Figure 8A) or DEX-induced repression of
CBG mRNA and protein expression (Figure 8B, C&D). However,
the siRNA specific decrease in C/EBPb protein expression
resulted in a significant (p,0.01) abrogation of DEX-induced
repression of CBG mRNA and protein expression in BWTG3 cells
(Figure 8B, C&D).
Furthermore, to establish whether occupancy of ligand-activat-
ed GR on the Cbg gene promoter is dependent on C/EBPb, ChIP
assays were performed with cells transfected with C/EBPb-specific
siRNA oligo’s to decrease C/EBPb protein expression. As shown
in Figure 8E, when C/EBPb protein expression was decreased,
GR recruitment to the Cbg gene promoter in the presence of DEX
was significantly (p,0.05) diminished.
The results obtained with the C/EBPb knockdown experiments
(Figure 8), together with the site-directed mutagenesis experiments
(Figure 6) and the ChIP results presented in Figure 7 strongly
suggest that DEX-induced repression of CBG involves C/EBPb.
The GR together with C/EBPb occupies the C/EBPb cis-
regulatory element of the Cbg promoter
Ligand-activated GR has been shown to interact with C/EBPb
[35]. To assess whether these transcription factors co-occupy the
Cbg promoter in response to DEX, a re-ChIP assay was performed
using an anti-GR antibody for the first immunoprecipitation (IP1),
followed by the second immunoprecipitation (IP2) step using an
anti-C/EBPb-specific antibody. The results show that both GR
and C/EBPb are present in a complex and, in response to DEX
treatment are recruited to the Cbg promoter encompassing regions
P1–P5 (Figure 8F).
Discussion
CBG has been extensively characterized as a carrier protein
[4,7,14] and as a reservoir of endogenous GCs [19]. Because CBG
levels directly affect GC bioavailability and consequently GC
signaling in homeostatic stress responses, evaluation of factors that
modulate CBG levels are of interest.
The current study focused on the molecular mechanism of GC-
mediated inhibition of CBG expression. GCs are the major
hormone secreted during stress and we show that a variety of
stressors, both physical and psychological, influenced CBG mRNA
levels in vivo (Figure 2). In addition, we found that the severity of
the stressor modulated the amplitude of the response. Specifically,
voluntary running, considered the least stressful intervention,
showed little effect on hepatic CBG mRNA expression, while both
of the involuntary stressors, swimming (physical) and restraint
(psychological), resulted in a significant inhibition of CBG mRNA.
The psychological stress induced through restraint of the rats,
considered the most stressful event, showed the highest inhibition
(55%) of rat CBG mRNA expression. These results suggest (i) that
the severity of the stressor influences the degree of CBG expression
modulation, and (ii) that stress affects CBG expression at a
transcriptional level. This is in agreement with earlier reports for
both rats and humans [7,13,15,17]. During stress endogenous GCs
are released from the adrenals due to the activation of the
hypothalamic-pituitary-adrenal (HPA) axis and the resulting
increased circulating levels of GCs are believed to be responsible
for the inhibition of CBG expression [7]. In support of the fact that
GCs directly regulate CBG expression, we observed that treatment
with the potent GC, DEX, on its own resulted in a significant
decrease in both CBG mRNA and protein levels in hepatoma cell
lines (Figure 3). This is in agreement with a previous study
showing that in rats treated with DEX for 48 hrs, hepatic CBG
mRNA levels and CBG serum protein concentrations were
significantly decreased [31].
Having shown that stress, and specifically GCs, repress CBG
levels we determined that the effect is mediated by the GR, the
ligand-activated transcription factor required for the intracellular
effects of GCs (Figure 4) [44]. Specifically, we showed that
overexpression of GR potentiated the DEX-induced repression of
CBG (Figure 4B), whereas co-treatment with the GR antagonist,
RU486, attenuated DEX-mediated repression of a Cbg promoter
construct (Figure 4C). Furthermore, recruitment of the GR to the
Cbg gene promoter increased in response to DEX (Figure 7A).
These results suggest that the GR plays an important role in GC-
mediated repression of CBG and is supported by a previous study
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showing that mice without a functional GR were resistant to DEX-
mediated repression of hepatic CBG mRNA [30].
Despite the fact that the proximal promoters of the CBG gene
have been cloned and that five putative transcription factor-
binding sites (P1–P5) within the sequence have been identified
(Figure 1) [25], the current study is the first to investigate the cis-
acting elements involved in GC regulation. Initial experiments
delineating the DEX-responsiveness of the Cbg promoter estab-
lished that the region encompassing 2145 bp from the transcrip-
tion start site, which contains P1 and P2, was unresponsive to
DEX treatment (Figure 5). The cis-regulatory elements associated
with P1 and P2 have previously been identified as HNF1b and
CP2 [29], respectively, and, although the current study established
that these cis-regulatory elements are not important for DEX-
mediated repression of CBG, the region was previously shown to
be transcriptionally active and is probably required for minimal
promoter activity [25].
As the region 2295 bp from the transcription start site, which
encompasses P1–P5, resulted in DEX-induced repression of the
Cbg promoter (Figure 5) and recruited GR (Figure 7A), this left
the binding sites P3–P5, as possible candidates for DEX-mediated
repression of CBG expression. P3–P5 have been suggested to
resemble recognition sequences for DBP, HNF3a and C/EBPb,
respectively [25], although this has not yet been unequivocally
demonstrated experimentally. Site-directed mutagenesis of C/
EBPb (2216/2236), HNF3a (2189/2214), and DBP (2148/2
170) binding sites in the Cbg promoter narrowed down the
candidate cis-acting elements and identified the C/EBPb cis-
regulatory site, but not HNF3a or DBP, as important in DEX-
induced repression of CBG (Figure 6). In addition, a decrease in
C/EBPb protein expression by siRNA resulted in the attenuation
of DEX-induced repression of CBG mRNA and protein
expression in BWTG3 cells (Figure 8B, C&D), as well as GR
recruitment to the Cbg promoter (Figure 8E).
In further support of C/EBPb’s involvement in GC-mediated
repression of CBG, we also show that the GR together with C/
EBPb co-exist in a complex that occupies the C/EBPb cis-
regulatory position (Figure 8F). In addition, ChIP results (Fig-
ure 7B) also suggest that ligand-activated GR does not disturb C/
EBPb occupancy, thereby inhibiting transcription as reported for
IL-1b [45]. Rather, CBG inhibition appears to resemble COX-2
repression by GCs, which requires C/EBPb and GR to form a
protein-protein interaction in occupying the COX-2 promoter
[46]. The data in this study would suggest that the molecular
mechanism of GR-induced repression of CBG is similar to that
proposed for COX-2 and many other pro-inflammatory genes
inhibited by GCs. This would entail that the ligand-activated GR
physically interacts with C/EBPb, possibly via a tethering
mechanism whereby both transcription factors are present on
the Cbg promoter. Physical interaction of the GR with C/EBPb
has been described for genes that are positively and negatively
regulated by GCs, most of which are involved in inflammation
[35,46–49]. Further support for a tethering mechanism comes
from previous work in our laboratory, indicating that that a GR
monomer rather than a GR dimer is involved in DEX-mediated
repression of CBG [32,33].
C/EBPb is a ubiquitously expressed transcription factor
involved in the regulation of numerous cellular responses and
plays an important role in regulating liver function [50–52]. C/
EBPb is especially known to be an important regulator of the acute
phase response (APR) [52]. It modulates the expression of various
acute phase proteins (APPs), such as a1-acid glycoprotein and
haptoglobin [53–55], as well as modulating the expression of acute
phase cytokines, all of which, like CBG, contain binding motifs for
C/EBPb within their promoters [56,57]. The APR is the first
response to various stressors, such as injury, bacterial infection or
systemic inflammation, and is activated by inflammatory media-
tors, such as tumor necrosis factor alpha (TNFa), IL-1b, IL-6, and
GCs. C/EBPb is transcriptionally and post-translationally activat-
ed by these early inflammatory stimuli all of which contribute to
the activation of the APR [52,58]. A number of APPs are
synergistically regulated by GCs and C/EBPb [59]. Positive APPs,
like a1 acid-glycoprotein, C-reactive protein (CRP), and serum
amyloid A (SAA), are known to be regulated by GCs presumably
through protein-protein interaction of the GR with C/EBPb
although the exact molecular mechanism has not been established
for all APPs mentioned [58–63]. GC activation of CRP and SAA
was reported to be inhibited, when C/EBPb protein expression
was decreased by siRNA. The authors, however, did not
investigate any possible tethering mechanism of ligand-activated
GR and C/EBPb [59]. They did, however, show increased C/
EBPb binding to DNA in response to GC treatment as determined
by EMSA’s [59]. This finding is in agreement with the observation
made in the present study of C/EBPb’s recruitment to the Cbg
promoter in response to DEX (Figure 7B). Furthermore, a recent
study identified C/EBPb, to be important in GR signaling
especially in the liver, as most GR binding to DNA occurs at
accessible chromatin sites preoccupied by C/EBPb [36].
In conclusion, physiological stress or intake of exogenous GCs
decreases CBG levels, which have a direct effect on GC
bioavailability. It is well established that GCs negatively affect
their own carrier protein, and earlier studies suggested that GC-
mediated downregulation of CBG occurs at a transcriptional level
via the GR, in agreement with the findings of the present study. In
addition, cumulative evidence presented here strongly suggests
that ligand-activated GR tethers to C/EBPb, which results in GC-
mediated repression of CBG gene expression. Lower CBG levels
have been linked to obesity and insulin resistance, as it has been
shown to affect fat accumulation and muscle development
probably due to an increase in circulating GCs [4,64–69],
although hypocortisolism has also been associated with CBG
deficiency attributed to CBG functioning as a reservoir for
endogenous glucocorticoids [70,71]. Nonetheless, chronic stress or
inflammation would affect CBG levels thereby directly influencing
GC signaling. This study has deciphered the molecular mecha-
nism whereby GCs influence CBG transcription levels.
Acknowledgments
Carmen Langeveldt is acknowledged for tissue culture support.
Author Contributions
Conceived and designed the experiments: NJV WvB GH JH AL.
Performed the experiments: NJV FA-R WvB CS AL. Analyzed the data:
NJV FA-R AL. Contributed reagents/materials/analysis tools: JH AL.
Contributed to the writing of the manuscript: NJV AL. Revising article
critically for important intellectual content: NJV FA-R WvB CS GH JH
AL. Final approval of the version to be published: NJV FA-R WvB CS GH
JH AL.
Down-Regulation of CBG by Glucocorticoids Involves C/EBPb
PLOS ONE | www.plosone.org 12 October 2014 | Volume 9 | Issue 10 | e110702
References
1. Pugeat M, Bonneton A, Perrot D, Rocle-Nicolas B, Lejeune H, et al. (1989)
Decreased immunoreactivity and binding activity of corticosteroid-binding
globulin in serum in septic shock. Clin Chem 35: 1675–1679.
2. Garrel DR (1996) Corticosteroid-Binding Globulin during Inflammation and
Burn Injury: Nutritional Modulation and Clinical Implications. Hormone
Research in Paediatrics 45: 245–251.
3. Hammond GL (1990) Molecular Properties of Corticosteroid Binding Globulin
and the Sex-Steroid Binding Proteins. Endocr Rev 11: 65–79.
4. Perogamvros I, Ray DW, Trainer PJ (2012) Regulation of cortisol bioavailabil-
ity-effects on hormone measurement and action. Nat Rev Endocrinol 8: 717–
727.
5. Lewis JG, Mo¨pert B, Shand BI, Doogue MP, Soule SG, et al. (2006) Plasma
Variation of Corticosteroid-binding Globulin and Sex Hormone-binding
Globulin. Horm Metab Res 38: 241–245.
6. Dey R, Roychowdhury P (2003) Homology model of human corticosteroid
binding globulin: a study of its steroid binding ability and a plausible mechanism
of steroid hormone release at the site of inflammation. Journal of Molecular
Modeling 9: 183–189.
7. Henley DE, Lightman SL (2011) New insights into corticosteroid-binding
globulin and glucocorticoid delivery. Neuroscience 180: 1–8.
8. Petersen HH, Andreassen TK, Breiderhoff T, Brasen JH, Schulz H, et al. (2006)
Hyporesponsiveness to glucocorticoids in mice genetically deficient for the
corticosteroid binding globulin. Mol Cell Biol 26: 7236–7245.
9. Cizza G, Rother KI (2012) Cortisol binding globulin: more than just a carrier?
J Clin Endocrinol Metab 97: 77–80.
10. Mendel CM (1989) The free hormone hypothesis: a physiologically based
mathematical model. Endocr Rev 10: 232–274.
11. Mendel CM, Kuhn RW, Weisiger RA, Cavalieri RR, Siiteri PK, et al. (1989)
Uptake of cortisol by the perfused rat liver: validity of the free hormone
hypothesis applied to cortisol. Endocrinology 124: 468–476.
12. Mendel CM (1992) The Free Hormone Hypothesis Distinction from the Free
Hormone Transport Hypothesis. Journal of Andrology 13: 107–116.
13. Spencer RL, Miller AH, Moday H, McEwen BS, Blanchard RJ, et al. (1996)
Chronic social stress produces reductions in available splenic type II
corticosteroid receptor binding and plasma corticosteroid binding globulin
levels. Psychoneuroendocrinology 21: 95–109.
14. Moisan MP (2010) Genotype-phenotype associations in understanding the role
of corticosteroid-binding globulin in health and disease animal models. Mol Cell
Endocrinol 316: 35–41.
15. Ho JT, Al-Musalhi H, Chapman MJ, Quach T, Thomas PD, et al. (2006) Septic
shock and sepsis: a comparison of total and free plasma cortisol levels. J Clin
Endocrinol Metab 91: 105–114.
16. Kumsta R, Entringer S, Hellhammer DH, Wust S (2007) Cortisol and ACTH
responses to psychosocial stress are modulated by corticosteroid binding globulin
levels. Psychoneuroendocrinology 32: 1153–1157.
17. Fleshner M, Deak T, Spencer RL, Laudenslager ML, Watkins LR, et al. (1995)
A long-term increase in basal levels of corticosterone and a decrease in
corticosteroid-binding globulin after acute stressor exposure. Endocrinology 136:
5336–5342.
18. Strehl C, Buttgereit F (2013) Optimized glucocorticoid therapy: Teaching old
drugs new tricks. Mol Cell Endocrinol.
19. Coolens JL, Van Baelen H, Heyns W (1987) Clinical use of unbound plasma
cortisol as calculated from total cortisol and corticosteroid-binding globulin.
J Steroid Biochem 26: 197–202.
20. Schlechte JA, Hamilton D (1987) The effect of glucocorticoids on corticosteroid
binding globulin. Clinical Endocrinology 27: 197–203.
21. Tinnikov AA (1999) Responses of serum corticosterone and corticosteroid-
binding globulin to acute and prolonged stress in the rat. Endocrine 11: 145–
150.
22. Deak T, Meriwether JL, Fleshner M, Spencer RL, Abouhamze A, et al. (1997)
Evidence that brief stress may induce the acute phase response in rats.
Am J Physiol 273: R1998–2004.
23. Beishuizen A, Thijs LG, Vermes I (2002) Decreased levels of dehydroepian-
drosterone sulphate in severe critical illness: a sign of exhausted adrenal reserve?
Crit Care 6: 434–438.
24. Roth-Isigkeit AK, Dibbelt L, Schmucker P (2000) Blood levels of corticosteroid-
binding globulin, total cortisol and unbound cortisol in patients undergoing
coronary artery bypass grafting surgery with cardiopulmonary bypass. Steroids
65: 513–520.
25. Underhill D, Hammond G (1995) cis-regulatory elements within the proximal
promoter of the rat gene encoding corticosteroid-binding globulin. Gene 162:
205–211.
26. Underhill DA, Hammond GL (1989) Organization of the human corticosteroid
binding globulin gene and analysis of its 59-flanking region. Mol Endocrinol 3:
1448–1454.
27. Orava M, Zhao XF, Leiter E, Hammond GL (1994) Structure and
chromosomal location of the gene encoding mouse corticosteroid-binding
globulin: strain differences in coding sequence and steroid-binding activity. Gene
144: 259–264.
28. Li Y, Wu L, Lei J, Zhu C, Wang H, et al. (2012) Single nucleotide
polymorphisms in the human corticosteroid-binding globulin promoter alter
transcriptional activity. Sci China Life Sci 55: 699–708.
29. Zhao X-F, Underhill DA, Hammond GL (1997) Hepatic nuclear proteins that
bind cis-regulatory elements in the proximal promoter of the rat corticosteroid-
binding globulin gene. Molecular and Cellular Endocrinology 126: 203–212.
30. Cole TJ, Harris HJ, Hoong I, Solomon N, Smith R, et al. (1999) The
glucocorticoid receptor is essential for maintaining basal and dexamethasone-
induced repression of the murine corticosteroid-binding globulin gene.
Molecular and Cellular Endocrinology 154: 29–36.
31. Smith C, Hammond G (1992) Hormonal regulation of corticosteroid-binding
globulin biosynthesis in the male rat. Endocrinology 130: 2245–2251.
32. Robertson S, Allie-Reid F, Berghe WV, Visser K, Binder A, et al. (2010)
Abrogation of glucocorticoid receptor dimerization correlates with dissociated
glucocorticoid behavior of compound a. J Biol Chem 285: 8061–8075.
33. Visser K, Smith C, Louw A (2010) Interplay of the inflammatory and stress
systems in a hepatic cell line: interactions between glucocorticoid receptor
agonists and interleukin-6. Endocrinology 151: 5279–5293.
34. Wang JC, Stromstedt PE, Sugiyama T, Granner DK (1999) The phosphoenol-
pyruvate carboxykinase gene glucocorticoid response unit: identification of the
functional domains of accessory factors HNF3 beta (hepatic nuclear factor-3
beta) and HNF4 and the necessity of proper alignment of their cognate binding
sites. Mol Endocrinol 13: 604–618.
35. Zha Q, Wang Y, Fan Y, Zhu MY (2011) Dexamethasone-induced up-regulation
of the human norepinephrine transporter involves the glucocorticoid receptor
and increased binding of C/EBP-beta to the proximal promoter of norepi-
nephrine transporter. J Neurochem 119: 654–663.
36. Grontved L, John S, Baek S, Liu Y, Buckley JR, et al. (2013) C/EBP maintains
chromatin accessibility in liver and facilitates glucocorticoid receptor recruitment
to steroid response elements. EMBO J 32: 1568–1583.
37. Cirillo LA, Lin FR, Cuesta I, Friedman D, Jarnik M, et al. (2002) Opening of
compacted chromatin by early developmental transcription factors HNF3
(FoxA) and GATA-4. Mol Cell 9: 279–289.
38. Miesfeld R, Rusconi S, Godowski PJ, Maler BA, Okret S, et al. (1986) Genetic
complementation of a glucocorticoid receptor deficiency by expression of cloned
receptor cDNA. Cell 46: 389–399.
39. Pfaffl MW (2001) A new mathematical model for relative quantification in real-
time RT-PCR. Nucleic Acids Res 29: e45.
40. Bradford MM (1976) A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye binding.
Analytical Biochemistry 72: 248–254.
41. Aparicio O, Geisberg JV, Struhl K (2004) Chromatin Immunoprecipitation for
Determining the Association of Proteins with Specific Genomic Sequences In
Vivo. Current Protocols in Cell Biology 17: 17.17.11–17.17.23.
42. Lesage J, Dufourny L, Laborie C, Bernet F, Blondeau B, et al. (2002) Perinatal
malnutrition programs sympathoadrenal and hypothalamic-pituitary-adrenal
axis responsiveness to restraint stress in adult male rats. J Neuroendocrinol 14:
135–143.
43. Emptoz-Bonneton A, Crave JC, LeJeune H, Brebant C, Pugeat M (1997)
Corticosteroid-binding globulin synthesis regulation by cytokines and glucocor-
ticoids in human hepatoblastoma-derived (HepG2) cells. J Clin Endocrinol
Metab 82: 3758–3762.
44. Heitzer M, Wolf I, Sanchez E, Witchel S, DeFranco D (2007) Glucocorticoid
receptor physiology. Reviews in Endocrine and Metabolic Disorders 8: 321–330.
45. Waterman WR, Xu LL, Tetradis S, Motyckova G, Tsukada J, et al. (2006)
Glucocorticoid inhibits the human pro-interleukin lb gene (ILIB) by decreasing
DNA binding of transactivators to the signal-responsive enhancer. Molecular
Immunology 43: 773–782.
46. Sun H, Sheveleva E, Xu B, Inoue H, Bowden TG, et al. (2008) Corticosteroids
induce COX-2 expression in cardiomyocytes: role of glucocorticoid receptor and
C/EBP-beta. Am J Physiol Cell Physiol 295: C915–922.
47. Johansson-Haque K, Palanichamy E, Okret S (2008) Stimulation of MAPK-
phosphatase 1 gene expression by glucocorticoids occurs through a tethering
mechanism involving C/EBP. J Mol Endocrinol 41: 239–249.
48. Roos AB, Nord M (2012) The emerging role of C/EBPs in glucocorticoid
signaling: lessons from the lung. J Endocrinol 212: 291–305.
49. Boruk M, Savory JG, Hache RJ (1998) AF-2-dependent potentiation of CCAAT
enhancer binding protein beta-mediated transcriptional activation by glucocor-
ticoid receptor. Mol Endocrinol 12: 1749–1763.
50. Ruminy P, Gangneux C, Claeyssens S, Scotte M, Daveau M, et al. (2001) Gene
transcription in hepatocytes during the acute phase of a systemic inflammation:
from transcription factors to target genes. Inflamm Res 50: 383–390.
51. Cappelletti M, Alonzi T, Fattori E, Libert C, Poli V (1996) C/EBPbeta is
required for the late phases of acute phase genes induction in the liver and for
tumour necrosis factor-alpha, but not Interleukin-6, regulation. Cell Death
Differ 3: 29–35.
52. Poli V (1998) The Role of C/EBP Isoforms in the Control of Inflammatory and
Native Immunity Functions. Journal of Biological Chemistry 273: 29279–29282.
53. Koj A (1996) Initiation of acute phase response and synthesis of cytokines.
Biochim Biophys Acta 1317: 84–94.
Down-Regulation of CBG by Glucocorticoids Involves C/EBPb
PLOS ONE | www.plosone.org 13 October 2014 | Volume 9 | Issue 10 | e110702
54. Ramji DP, Vitelli A, Tronche F, Cortese R, Ciliberto G (1993) The two C/EBP
isoforms, IL-6DBP/NF-IL6 and C/EBP delta/NF-IL6 beta, are induced by IL-
6 to promote acute phase gene transcription via different mechanisms. Nucleic
Acids Res 21: 289–294.
55. Kurash JK, Shen CN, Tosh D (2004) Induction and regulation of acute phase
proteins in transdifferentiated hepatocytes. Exp Cell Res 292: 342–358.
56. Grigorov I, Milosavljevic T, Cvetkovic I, Petrovic M (1998) Participation of two
isoforms of C/EBPbeta transcription factor in the acute-phase regulation of the
rat haptoglobin gene. Cell Biol Int 22: 685–693.
57. Akira S, Kishimoto T (1992) IL-6 and NF-IL6 in acute-phase response and viral
infection. Immunol Rev 127: 25–50.
58. Alam T, An MR, Mifflin RC, Hsieh CC, Ge X, et al. (1993) trans-activation of
the alpha 1-acid glycoprotein gene acute phase responsive element by multiple
isoforms of C/EBP and glucocorticoid receptor. J Biol Chem 268: 15681–
15688.
59. Zhang N, Truong-Tran QA, Tancowny B, Harris KE, Schleimer RP (2007)
Glucocorticoids enhance or spare innate immunity: effects in airway epithelium
are mediated by CCAAT/enhancer binding proteins. J Immunol 179: 578–589.
60. Nishio Y, Isshiki H, Kishimoto T, Akira S (1993) A nuclear factor for
interleukin-6 expression (NF-IL6) and the glucocorticoid receptor synergistically
activate transcription of the rat alpha 1-acid glycoprotein gene via direct protein-
protein interaction. Mol Cell Biol 13: 1854–1862.
61. Mouthiers A, Baillet A, Delomenie C, Porquet D, Mejdoubi-Charef N (2005)
Peroxisome proliferator-activated receptor alpha physically interacts with
CCAAT/enhancer binding protein (C/EBPbeta) to inhibit C/EBPbeta-
responsive alpha1-acid glycoprotein gene expression. Mol Endocrinol 19:
1135–1146.
62. Savoldi G, Fenaroli A, Ferrari F, Rigaud G, Albertini A, et al. (1997) The
glucocorticoid receptor regulates the binding of C/EPBbeta on the alpha-1-acid
glycoprotein promoter in vivo. DNA Cell Biol 16: 1467–1476.
63. Boudreau F, Yu SJ, Asselin C (1998) CCAAT/enhancer binding proteins beta
and delta regulate alpha1-acid glycoprotein gene expression in rat intestinal
epithelial cells. DNA Cell Biol 17: 669–677.
64. Gagliardi L, Ho JT, Torpy DJ (2010) Corticosteroid-binding globulin: the
clinical significance of altered levels and heritable mutations. Mol Cell
Endocrinol 316: 24–34.
65. Ousova O, Guyonnet-Duperat V, Iannuccelli N, Bidanel JP, Milan D, et al.
(2004) Corticosteroid binding globulin: a new target for cortisol-driven obesity.
Mol Endocrinol 18: 1687–1696.
66. Fernandez-Real JM, Pugeat M, Lopez-Bermejo A, Bornet H, Ricart W (2005)
Corticosteroid-binding globulin affects the relationship between circulating
adiponectin and cortisol in men and women. Metabolism 54: 584–589.
67. Torpy DJ, Lundgren BA, Ho JT, Lewis JG, Scott HS, et al. (2012) CBG
Santiago: a novel CBG mutation. J Clin Endocrinol Metab 97: E151–155.
68. Emptoz-Bonneton A, Cousin P, Seguchi K, Avvakumov GV, Bully C, et al.
(2000) Novel human corticosteroid-binding globulin variant with low cortisol-
binding affinity. J Clin Endocrinol Metab 85: 361–367.
69. Vogeser M, Halser B, Baron A, Jacob K, Demant T (2000) Corticosteroid-
binding globulin and unbound serum cortisol in women with polycystic ovary
syndrome. Clin Biochem 33: 157–159.
70. Richard EM, Helbling JC, Tridon C, Desmedt A, Minni AM, et al. (2010)
Plasma transcortin influences endocrine and behavioral stress responses in mice.
Endocrinology 151: 649–659.
71. Raison CL, Miller AH (2003) When not enough is too much: the role of
insufficient glucocorticoid signaling in the pathophysiology of stress-related
disorders. Am J Psychiatry 160: 1554–1565.
Down-Regulation of CBG by Glucocorticoids Involves C/EBPb
PLOS ONE | www.plosone.org 14 October 2014 | Volume 9 | Issue 10 | e110702
